MA44608B1 - Récepteurs des lymphocytes t - Google Patents

Récepteurs des lymphocytes t

Info

Publication number
MA44608B1
MA44608B1 MA44608A MA44608A MA44608B1 MA 44608 B1 MA44608 B1 MA 44608B1 MA 44608 A MA44608 A MA 44608A MA 44608 A MA44608 A MA 44608A MA 44608 B1 MA44608 B1 MA 44608B1
Authority
MA
Morocco
Prior art keywords
cell receptors
tcrs
tcr
mage
gvydgrehtv
Prior art date
Application number
MA44608A
Other languages
English (en)
Other versions
MA44608A (fr
Inventor
Conor Hayes
Linda Hibbert
Nathaniel Liddy
Tara Mahon
Marine Raman
Original Assignee
Immunocore Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunocore Ltd filed Critical Immunocore Ltd
Publication of MA44608A publication Critical patent/MA44608A/fr
Publication of MA44608B1 publication Critical patent/MA44608B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention concerne des récepteurs de lymphocytes t (tcr) qui se lient au peptide à restriction hla-a*02 gvydgrehtv (seq id no : 1) dérivé de l'antigène de cancer de lignée germinale mage a4. Ces tcr peuvent comprendre des mutations non naturelles dans les domaines variables alpha et/ou bêta par rapport à un tcr de mage a4 natif. Les tcr de l'invention sont particulièrement aptes à être utilisés en tant que nouveaux réactifs immunothérapeutiques pour le traitement de maladies malignes.
MA44608A 2016-04-08 2017-04-07 Récepteurs des lymphocytes t MA44608B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB201606009 2016-04-08
PCT/GB2017/050985 WO2017175006A1 (fr) 2016-04-08 2017-04-07 Récepteurs des lymphocytes t

Publications (2)

Publication Number Publication Date
MA44608A MA44608A (fr) 2019-02-13
MA44608B1 true MA44608B1 (fr) 2022-06-30

Family

ID=58548761

Family Applications (1)

Application Number Title Priority Date Filing Date
MA44608A MA44608B1 (fr) 2016-04-08 2017-04-07 Récepteurs des lymphocytes t

Country Status (31)

Country Link
US (2) US11505590B2 (fr)
EP (2) EP4023668A1 (fr)
JP (1) JP7254519B2 (fr)
KR (1) KR102473964B1 (fr)
CN (1) CN109563148B (fr)
AU (2) AU2017246693B2 (fr)
BR (1) BR112018070741A2 (fr)
CL (1) CL2018002859A1 (fr)
CO (1) CO2018011972A2 (fr)
CR (1) CR20180531A (fr)
CY (1) CY1125331T1 (fr)
DK (1) DK3440105T3 (fr)
ES (1) ES2914648T3 (fr)
HR (1) HRP20220865T1 (fr)
HU (1) HUE059159T2 (fr)
IL (2) IL262144B2 (fr)
LT (1) LT3440105T (fr)
MA (1) MA44608B1 (fr)
MD (1) MD3440105T2 (fr)
MX (1) MX2018012318A (fr)
MY (1) MY198621A (fr)
PE (2) PE20190335A1 (fr)
PH (1) PH12018502158B1 (fr)
PL (1) PL3440105T3 (fr)
PT (1) PT3440105T (fr)
RS (1) RS63371B1 (fr)
SG (1) SG11201808797XA (fr)
SI (1) SI3440105T1 (fr)
SM (1) SMT202200306T1 (fr)
UA (1) UA129144C2 (fr)
WO (1) WO2017175006A1 (fr)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3020555A1 (fr) 2016-04-08 2017-10-12 Adaptimmune Limited Recepteurs des lymphocytes t
KR20190059874A (ko) * 2016-04-08 2019-05-31 어댑티뮨 리미티드 T 세포 수용체
PL3440105T3 (pl) 2016-04-08 2022-08-29 Immunocore Limited Receptory komórek t
BR112020006643A2 (pt) 2017-10-03 2020-09-24 Juno Therapeutics Inc moléculas de ligação específica ao hpv
WO2019133443A1 (fr) * 2017-12-28 2019-07-04 Janux Therapeutics, Inc. Récepteurs de lymphocytes t modifiés
GB201803750D0 (en) 2018-03-08 2018-04-25 Immunocore Ltd Method
CA3094468A1 (fr) * 2018-04-05 2019-10-10 Juno Therapeutics, Inc. Procedes de production de cellules exprimant un recepteur recombinant et compositions associees
ES2974424T3 (es) 2019-01-17 2024-06-27 Immunocore Ltd Formulaciones
GB201901306D0 (en) 2019-01-30 2019-03-20 Immunocore Ltd Multi-domain binding molecules
GB201901305D0 (en) 2019-01-30 2019-03-20 Immunocore Ltd Specific binding molecules
EP3714941A1 (fr) * 2019-03-27 2020-09-30 Medigene Immunotherapies GmbH Récepteurs de lymphocytes t de mage-a4
KR20220030933A (ko) 2019-05-08 2022-03-11 메디진 이뮤노테라피스 게엠바하 조작된 t 세포
BR112021025548A2 (pt) * 2019-06-18 2022-05-17 Regeneron Pharma Receptores de células t mage-a4 e métodos de uso dos mesmos
CR20210687A (es) 2019-06-25 2022-03-03 Gilead Sciences Inc PROTEÍNAS DE FUSIÓN FLT3L-Fc Y MÉTODOS DE USO
US12480958B2 (en) 2019-08-13 2025-11-25 Immatics Biotechnologies Gmbh Method for the characterization of peptide:MHC binding polypeptides
GB201915282D0 (en) * 2019-10-22 2019-12-04 Immunocore Ltd Specific binding molecules
CR20220256A (es) * 2019-12-18 2022-08-31 Hoffmann La Roche Anticuerpos que se unen a hla-a2/mage-a4
KR20260017503A (ko) 2020-02-14 2026-02-05 길리애드 사이언시즈, 인코포레이티드 Ccr8에 결합하는 항체 및 융합 단백질, 및 이의 용도
WO2021236548A1 (fr) * 2020-05-18 2021-11-25 Board Of Regents, The University Of Texas System Récepteurs de lymphocytes t modifiés et leurs procédés d'utilisation
US12312412B2 (en) 2020-05-19 2025-05-27 Amgen Inc. MAGEB2 binding constructs
TWI815194B (zh) 2020-10-22 2023-09-11 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
US11912771B2 (en) 2021-03-09 2024-02-27 Cdr-Life Ag MAGE-A4 peptide-MHC antigen binding proteins
EP4304725A1 (fr) 2021-03-09 2024-01-17 CDR-Life AG Bibliothèques d'acides nucléiques de protéines de liaison à l'antigène de lapin
TW202313094A (zh) 2021-05-18 2023-04-01 美商基利科學股份有限公司 使用ＦＬＴ３Ｌ—Ｆｃ融合蛋白之方法
US20230183216A1 (en) 2021-10-28 2023-06-15 Gilead Sciences, Inc. Pyridizin-3(2h)-one derivatives
EP4422756A1 (fr) 2021-10-29 2024-09-04 Gilead Sciences, Inc. Composés cd73
WO2023099606A1 (fr) 2021-12-01 2023-06-08 Immunocore Limited Traitement d'un cancer mage-a4 positif
CN118488946A (zh) 2021-12-22 2024-08-13 吉利德科学公司 Ikaros锌指家族降解剂及其用途
EP4452415B1 (fr) 2021-12-22 2026-02-25 Gilead Sciences, Inc. Agents de dégradation des doigts de zinc de la famille ikaros et leurs utilisations
TW202340168A (zh) 2022-01-28 2023-10-16 美商基利科學股份有限公司 Ｐａｒｐ７抑制劑
CA3253296A1 (fr) 2022-03-17 2023-09-21 Gilead Sciences, Inc. Agents de dégradation des doigts de zinc de la famille ikaros et leurs utilisations
WO2023205719A1 (fr) 2022-04-21 2023-10-26 Gilead Sciences, Inc. Composés modulateurs de kras g12d
CN117106060A (zh) * 2022-05-17 2023-11-24 香雪生命科学技术（广东）有限公司 一种识别mage的高亲和力t细胞受体及其应用
US20240116928A1 (en) 2022-07-01 2024-04-11 Gilead Sciences, Inc. Cd73 compounds
MX2025001960A (es) 2022-08-18 2025-05-02 Immunocore Ltd Moléculas de unión multidominio
KR20250051727A (ko) 2022-08-18 2025-04-17 이뮤노코어 리미티드 멀티-도메인 결합 분자
KR20250051722A (ko) 2022-08-18 2025-04-17 이뮤노코어 리미티드 멀티-도메인 결합 분자
CA3265218A1 (fr) 2022-08-18 2024-02-22 Immunocore Ltd Protéines de fusion de récepteurs de lymphocytes t spécifiques de mage a4
KR20250067130A (ko) * 2022-09-14 2025-05-14 씨디알-라이프 아게 Mage-a4 펩티드 이중 t 세포 연결체
EP4638436A1 (fr) 2022-12-22 2025-10-29 Gilead Sciences, Inc. Inhibiteurs de prmt5 et leurs utilisations
CN120882725A (zh) 2023-04-11 2025-10-31 吉利德科学公司 Kras调节化合物
WO2024220917A1 (fr) 2023-04-21 2024-10-24 Gilead Sciences, Inc. Inhibiteurs de prmt5 et leurs utilisations
US20250042922A1 (en) 2023-06-30 2025-02-06 Gilead Sciences, Inc. Kras modulating compounds
AU2024297978A1 (en) 2023-07-26 2026-02-05 Gilead Sciences, Inc. Parp7 inhibitors
US20250066328A1 (en) 2023-07-26 2025-02-27 Gilead Sciences, Inc. Parp7 inhibitors
CN119552258B (zh) 2023-09-01 2025-11-07 北京智仁美博生物科技有限公司 结合hla-a02/mage-a4复合体的多种抗体及其用途
WO2025054347A1 (fr) 2023-09-08 2025-03-13 Gilead Sciences, Inc. Composés de modulation de kras g12d
AU2024337913A1 (en) 2023-09-08 2026-03-26 Gilead Sciences, Inc. Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds
GB202315181D0 (en) 2023-10-03 2023-11-15 Immunocore Ltd Peptide-HLA binding molecules
WO2025087436A1 (fr) * 2023-10-27 2025-05-01 北京可瑞生物科技有限公司 Molécule polypeptidique multi-spécifique basée sur un récepteur de lymphocytes t, composition et utilisation associées
WO2025094054A1 (fr) 2023-11-01 2025-05-08 Immunocore Limited Procédé de purification de petites protéines à domaines multiples
US20250154172A1 (en) 2023-11-03 2025-05-15 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2025137640A1 (fr) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Inhibiteurs azaspiro de wrn
GB202320012D0 (en) 2023-12-22 2024-02-07 Immunocore Ltd Bispecific molecules
US20250376484A1 (en) 2024-05-21 2025-12-11 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
GB2641580A (en) 2024-06-07 2025-12-10 T Therapeutics Ltd Tumour-transforming multispecific proteins
WO2026039365A1 (fr) 2024-08-12 2026-02-19 Gilead Sciences, Inc. Composés de modulation de kras
WO2026078231A1 (fr) 2024-10-11 2026-04-16 T-Therapeutics Limited Ligand immunitaire non agrégant soluble

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6685698A (en) 1997-03-07 1998-09-22 Sunol Molecular Corporation Fusion proteins comprising bacteriophage coat protein and a single-chain t cell receptor
WO1999018129A1 (fr) 1997-10-02 1999-04-15 Sunol Molecular Corporation Proteines solubles du recepteur des lymphocytes t a chaine unique
WO2000020445A2 (fr) 1998-10-02 2000-04-13 Ludwig Institute For Cancer Research Antigenes tumoraux et clones de lymphocyte t cytotoxique (ctl) isoles grace a un nouveau procede
JP4972264B2 (ja) 1999-12-06 2012-07-11 ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ イリノイ 高親和性ｔｃｒタンパク質および方法
WO2001062908A2 (fr) 2000-02-22 2001-08-30 Ahuva Nissim Banques d'affichage de phages chimeriques et tcr, reactifs chimeriques et tcr et methodes d'utilisation correspondantes
AU2002321581C1 (en) 2001-08-31 2008-09-18 Adaptimmune Limited Soluble T cell receptor
JP2005537891A (ja) 2002-09-10 2005-12-15 ユーロ−セルティーク エス．エイ． 血液成分の非侵襲的測定のための装置及び方法
AU2003289716A1 (en) * 2002-09-12 2004-04-30 Incyte Corporation Molecules for diagnostics and therapeutics
AU2003271904B2 (en) 2002-10-09 2009-03-05 Adaptimmune Limited Single chain recombinant T cell receptors
DE60327795D1 (de) 2002-11-09 2009-07-09 Immunocore Ltd T zell rezeptor "display"
GB0304068D0 (en) * 2003-02-22 2003-03-26 Avidex Ltd Substances
NZ561338A (en) 2005-04-01 2010-04-30 Immunocore Ltd High affinity HIV T cell receptors
CN101287831B (zh) 2005-09-13 2013-05-15 国立大学法人三重大学 T细胞受体和编码该受体的核酸
GB0908613D0 (en) 2009-05-20 2009-06-24 Immunocore Ltd T Cell Reseptors
ES2834070T3 (es) 2011-09-15 2021-06-16 Us Health Receptores de células T que reconocen MAGE restringido por HLA-A1 o HLA-Cw7
WO2013053021A1 (fr) * 2011-10-14 2013-04-18 Cephalon Australia Pty Ltd Anticorps dirigés contre la cd1d
LT3424947T (lt) 2011-10-28 2021-03-10 Regeneron Pharmaceuticals, Inc. Genetiškai modifikuotos t ląstelių receptorių pelės
GB201223172D0 (en) 2012-12-21 2013-02-06 Immunocore Ltd Method
US10377808B2 (en) 2013-01-29 2019-08-13 Max-Delbrück-Centrum Für Molekulare Medizin (Mdc) Berlin-Buch High avidity antigen recognizing constructs
WO2014160030A2 (fr) 2013-03-13 2014-10-02 Health Research, Inc. Compositions et procédés pour l'utilisation de récepteurs de lymphocytes t recombinants pour la reconnaissance directe d'un antigène tumoral
WO2016007570A2 (fr) * 2014-07-09 2016-01-14 The Regents Of The University Of California Lymphocytes t tueurs naturels invariants (inkt) génétiquement modifiés procédés de production et d'utilisation de ceux-ci
CN107074970B (zh) 2014-08-04 2021-07-30 弗雷德哈钦森癌症研究中心 特异性针对wt-1的t细胞免疫疗法
EP3283520B1 (fr) 2015-04-13 2020-05-06 Pfizer Inc Récepteurs antigéniques chimériques ciblant l'antigène de maturation des cellules b
ES2968802T3 (es) 2016-03-16 2024-05-14 Immatics Biotechnologies Gmbh Células T transfectadas y receptores de células T para su uso en inmunoterapia contra el cáncer
PT3436079T (pt) 2016-04-01 2021-10-06 Kite Pharma Inc Recetores de antigénios quiméricos e de células t e métodos de uso
PL3440105T3 (pl) 2016-04-08 2022-08-29 Immunocore Limited Receptory komórek t
GB201901306D0 (en) 2019-01-30 2019-03-20 Immunocore Ltd Multi-domain binding molecules

Also Published As

Publication number Publication date
KR20180132844A (ko) 2018-12-12
CL2018002859A1 (es) 2019-04-26
IL262144B2 (en) 2024-04-01
CN109563148A (zh) 2019-04-02
HRP20220865T1 (hr) 2022-10-14
PE20190335A1 (es) 2019-03-07
EP3440105A1 (fr) 2019-02-13
EP3440105B1 (fr) 2022-04-27
DK3440105T3 (da) 2022-06-13
JP2019516357A (ja) 2019-06-20
UA129144C2 (uk) 2025-01-29
IL262144B1 (en) 2023-12-01
CN109563148B (zh) 2022-10-14
AU2017246693A1 (en) 2018-11-22
SI3440105T1 (sl) 2022-07-29
US12606607B2 (en) 2026-04-21
PL3440105T3 (pl) 2022-08-29
MD3440105T2 (ro) 2022-09-30
IL262144A (en) 2018-11-29
PH12018502158A1 (en) 2019-07-15
EP4023668A1 (fr) 2022-07-06
RS63371B1 (sr) 2022-08-31
CR20180531A (es) 2019-06-13
IL308831A (en) 2024-01-01
US20190092834A1 (en) 2019-03-28
CY1125331T1 (el) 2025-03-28
US11505590B2 (en) 2022-11-22
AU2017246693B2 (en) 2022-07-21
RU2018135248A3 (fr) 2020-09-23
CO2018011972A2 (es) 2019-02-08
US20230322895A1 (en) 2023-10-12
JP7254519B2 (ja) 2023-04-10
AU2022256131A1 (en) 2022-11-24
CA3020214A1 (fr) 2017-10-12
HUE059159T2 (hu) 2022-10-28
LT3440105T (lt) 2022-05-25
MY198621A (en) 2023-09-11
SMT202200306T1 (it) 2022-09-14
RU2018135248A (ru) 2020-05-12
BR112018070741A2 (pt) 2019-02-12
MA44608A (fr) 2019-02-13
KR102473964B1 (ko) 2022-12-06
PH12018502158B1 (en) 2024-02-02
SG11201808797XA (en) 2018-11-29
PE20240693A1 (es) 2024-04-10
PT3440105T (pt) 2022-05-31
ES2914648T3 (es) 2022-06-15
WO2017175006A1 (fr) 2017-10-12
MX2018012318A (es) 2019-07-04

Similar Documents

Publication Publication Date Title
MA44608B1 (fr) Récepteurs des lymphocytes t
ZA202306640B (en) T cell receptors
MA49236B1 (fr) Nouveaux récepteurs de lymphocytes t et immunothérapie les utilisant
AU2023200614B2 (en) Anti-mutated KRAS T cell receptors
Ploegh et al. Major histocompatibility antigens: the human (HLA-A,-B,-C) and murine (H-2K, H-2D) class I molecules
MA45976B1 (fr) Récepteurs de lymphocytes t et thérapie immunitaire les utilisant
US20200270329A1 (en) T cell receptors recognizing mhc class ii-restricted mage-a3
Albert et al. Histocompatibility Testing 1984: Report on the Ninth International Histocompatibility Workshop and Conference Held in Munich, West Germany, May 6–11, 1984 and in Vienna, Austria, May 13–15, 1984
MX2022004906A (es) Moleculas de union especifica.
MA45309B1 (fr) Lymphocytes t transfectés et récepteurs de lymphocytes t destinés à être utilisés en immunothérapie contre des cancers
MA43330A1 (fr) Lymphocytes t transfectés et récepteurs de lymphocytes t destinés à être utilisés en immunothérapie contre des cancers
MA43435B1 (fr) Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie contre diverses tumeurs (seq id 25 - mrax5-003)
KR20220079645A (ko) Ｋｒａｓ 돌연변이를 식별하는 ｔ 세포 수용체 및 그 코딩서열
MA43457A1 (fr) Nouveaux peptides, combinaisons de peptides et supports pour utilisation dans le traitementimmunothérapeutique de divers cancers
MA41867B1 (fr) Anticorps dirigés contre l'immunoglobuline de cellule t et protéine 3 de mucine (tim-3)
JP7735285B2 (ja) Ｇ１２ｖ突然変異ｒａｓに対するｈｌａクラスｉ拘束性ｔ細胞受容体
Rose et al. Lymphoma-selective antibody Lym-1 recognizes a discontinuous epitope on the light chain of HLA-DR10
Weissman et al. Tyrosine phosphorylation of the human T cell antigen receptor zeta-chain: activation via CD3 but not CD2.
Lake et al. Construction and binding analysis of recombinant single-chain TCR derived from tumor-infiltrating lymphocytes and a cytotoxic T lymphocyte clone directed against MAGE-1
Kwan Lim et al. Co‐capping studies reveal CD8/TCR interactions after capping CD8β polypeptides and intracellular associations of CD8 with p56lck
CL2025001873A1 (es) Proteínas de unión a antígenos de especificidad cruzada dirigidas a lilrb1 y lilrb2, combinaciones, usos
Ueno et al. HLA class I‐restricted recognition of an HIV‐derived epitope peptide by a human T cell receptor α chain having a Vδ1 variable segment
Hawke et al. Stimulation of human T cells by sparse antigens captured on immunomagnetic particles
Tran et al. Strong association of HLA-B27 heavy chain with β2-microglobulin
Pavlištová et al. A novel monoclonal reagent recognizing native and denatured Vβ5. 3-related chains of human T cell receptor